Why the study?
Does the expression of haem-free sGC (apo-sGC) alter the cardiovascular and pharmacological responses to NO and sGC activators in mice?
Does the expression of haem-free sGC (apo-sGC) alter the cardiovascular and pharmacological responses to NO and sGC activators in mice?
Apo-sGC mice demonstrate that haem-containing sGC is required for NO-mediated vasorelaxation and platelet inhibition, and provide an in vivo model showing that sGC activators like cinaciguat can effectively target oxidized, haem-free sGC.
Oxidative stress, a central mediator of cardiovascular disease, results in loss of the prosthetic haem group of soluble guanylate cyclase (sGC), preventing its activation by nitric oxide (NO). Here we introduce Apo-sGC mice expressing haem-free sGC. Apo-sGC mice are viable and develop hypertension. The haemodynamic effects of NO are abolished, but those of the sGC activator cinaciguat are enhanced in apo-sGC mice, suggesting that the effects of NO on smooth muscle relaxation, blood pressure regulation and inhibition of platelet aggregation require sGC activation by NO. Tumour necrosis factor (TNF)-induced hypotension and mortality are preserved in apo-sGC mice, indicating that pathways other than sGC signalling mediate the cardiovascular collapse in shock. Apo-sGC mice allow for differentiation between sGC-dependent and -independent NO effects and between haem-dependent and -independent sGC effects. Apo-sGC mice represent a unique experimental platform to study the in vivo consequences of sGC oxidation and the therapeutic potential of sGC activators.
No takes yet. Share an insight, caveat, or question.
Thoonen et al. (2015) studied Cardiovascular disease / Oxidative stress. Apo-sGC knock-in (H105F mutation) vs. Wild-type mice was evaluated on Hemodynamic response to NO and sGC activators.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: